Browse medicines
Some records contain detailed evidence; others currently contain only basic identity and regulatory information. Reviewed conclusions appear only when they are available for a specific use and group of people.
Medicine type
Approval status
AllApproved in the United States (FDA)Approved in the European Union (EMA)In Phase 3 testingIn Phase 2 testingUsed in a way not covered by an approval, or made by a compounding pharmacyDietary supplement; not FDA-approved as a medicineFDA accelerated approval (based on an earlier result expected to predict benefit; follow-up evidence may be required)Laboratory or animal-stage researchControlled substance; no approved US useWithdrawn from the market
Amount of information
Showing 1–3 of 3 records
Retatrutide (LY3437943 (no trade name; not approved))
Peptide medicineIn Phase 3 testingDetailed recordUse listed on the medicine record
Obesity and type 2 diabetes, still in trials
Survodutide (BI 456906 (no trade name; not approved))
Peptide medicineIn Phase 3 testingDetailed recordUse listed on the medicine record
Obesity and fatty liver disease, still in trials
TB-500 (thymosin beta-4) (Sold as TB-500. The full peptide is thymosin beta-4, developed as RGN-259 (eye drops) and NL005 (recombinant injection))
Peptide medicineIn Phase 3 testingDetailed recordUse listed on the medicine record
Sold for injury repair — nothing containing it is approved anywhere